Sight Sciences to Report First Quarter Financial Results on May 2, 2024
April 18, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt
April 12, 2024 04:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Kalifornien, April 12, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) („Sight Sciences“ oder das „Unternehmen“), ein Technologieunternehmen im Bereich der Augenheilkunde,...
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
April 10, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 02, 2024 16:05 ET
|
Sight Sciences, Inc.
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. ...
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
March 26, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
March 07, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and...
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
February 22, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
February 14, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
January 23, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
January 08, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...